Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 477 across all filing types
Latest filing 2022-11-10 Regulatory Filings
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Regulatory Filings
2022-11-10 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 70% confidence The document is a notification letter from Supriya Lifescience Limited to stock exchanges about an upcoming earnings call scheduled for November 11, 2022, to discuss the operational and financial performance for the quarter and half year ended September 30, 2022. It includes details such as the date, time, participants, and dial-in information for the call. The document does not contain actual financial results or detailed financial statements but serves as an announcement of the earnings call event. According to the classification rules, such a document is best classified as a Call Transcript (CT) category if it contained the full transcript, but since this is only an invitation/intimation for the earnings call, it is an announcement related to the call. However, the closest fitting category in the provided list for an earnings call announcement is Call Transcript (CT), as it relates directly to the earnings call event. The document length is short and does not contain financial data, so it is not an Earnings Release (ER) or Interim Report (IR). Therefore, the best classification is Call Transcript (CT) with moderate confidence due to the document being an invitation rather than the transcript itself.
2022-11-03 English
Board Meeting — Financial results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about an upcoming Board Meeting scheduled to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2022. It also mentions the closure of the trading window in compliance with insider trading regulations. The document does not contain any financial data or results itself, but is an announcement of a future event related to financial reporting. The length is short (2257 characters), and it serves as a notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about a board meeting and financial results release.
2022-11-02 English
General updates
Regulatory Filings Classification · 100% confidence The document is extremely short (300 characters) and contains only a digital signature with no substantive content or financial data. There is no indication of a report, announcement, or detailed information. This matches the pattern of an officer certification or attestation document. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2022-10-11 English
Press Release
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Mr. Rajeev Kumar Jain as Chief Executive Officer and Key Managerial Personnel of Supriya Lifescience Limited. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations. The content focuses on the appointment details, background of the appointee, and company information. There are no financial statements, earnings data, or detailed management discussion of financial results. The document is not a report but an announcement of a management change. Therefore, it fits the category of Board/Management Information (MANG). The document length (6455 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2022-10-03 English
Closure of trading window
Regulatory Filings Classification · 95% confidence The document is a notification titled 'Intimation of Trading Window Closure' addressed to stock exchanges regarding the closure of the trading window for insiders ahead of the announcement of unaudited financial results for the quarter and half year ended September 30, 2022. It references the upcoming financial results but does not contain any financial data or the results themselves. The document is short (2187 characters) and serves as an announcement related to compliance with insider trading regulations rather than a financial report. Therefore, it does not qualify as an Interim/Quarterly Report (IR) or Earnings Release (ER). It is best classified as a Regulatory Filing (RNS) because it is a regulatory compliance announcement that does not fit other categories.
2022-09-29 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.